Articles

Perspective

Published on 25 November 2019

An evolving role for non-governmental organizations dealing with registration backlogs and rising costs: the example of cancer biosimilars in South Africa

Abstract: Around the world, especially in low- and middle-income countries, national regulatory authorities are struggling with registration backlogs and the affordability of medicines. This paper draws on the example of...

Author(s): Paul Malherbe, PhD

biosimilars, non-governmental organizations, registration backlog, regulation

DOI: 10.5639/gabij.2020.0901.004

5.098 views

Read more →

Editor's Letter

Published on 25 November 2019

Latest features in GaBI Journal, 2019, Issue 3

Patients, their families and providers are facing increasing pressures related to the rapidly expanding global inequality which affects access to all components of a long, healthy, productive life including water,...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2019.0803.011

2.310 views

Read more →

Thank you to reviewers

Published on 02 October 2019

Thank you to reviewers 2018

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

1.917 views

Read more →

Published on 22 August 2019

2019/2 GaBI Journal Table of Contents

Contents Editor’s Letter Unmet potential of Generics and Biosimilars to reduce healthcare costs Original Research Pricing of oral generic cancer medicines in 25 European countries; findings and implications Review Article...

2.220 views

Read more →

Legal

Published on 21 August 2019

Policy recommendations for a sustainable biosimilars market: lessons from Europe

Author byline as per print journal: Professor Philip J Schneider1, MS, FASHP, FASPEN, FFIP; Michael S Reilly2, Esq Abstract: Approximately 25% of all new medicines approved in recent years and...

Author(s): Michael S Reilly, Esq, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP

biologicals/biosimilars, competition, patients, procurement, substitution, sustainability

DOI: 10.5639/gabij.2020.0902.013

17.186 views

Read more →

Editor's Letter

Published on 14 August 2019

Unmet potential of Generics and Biosimilars to reduce healthcare costs

The high cost of pharmaceuticals has been gaining increasing attention as a threat to both healthcare systems and patients’ access to care globally. This GaBI issue contains articles focusing on...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2019.0802.006

3.517 views

Read more →

Published on 29 May 2019

2019/1 GaBI Journal Table of Contents

Contents Editor’s Letter Editor’s introduction to the initial issue of the eighth volume of GaBI Journal Legal Biosimilars: considerations in light of the Italian legal framework Special Report Patent expiry...

2.363 views

Read more →

Editor's Letter

Published on 29 May 2019

Editor’s introduction to the initial issue of the eighth volume of GaBI Journal

This issue contains important information and manuscripts, but the small number of original papers illustrates the challenge the GaBI Journal (as well as many other legitimate journals) is having attracting...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2019.0801.001

2.642 views

Read more →

Abstracted Scientific Content

Published on 29 May 2019

Regulatory requirements for the acceptance of foreign comparator products in the participants of the International Generic Drug Regulators Programme

Submitted: 4 March 2019; Revised: 25 April 2019; Accepted: 27 April 2019; Published online first: 30 April 2019 The availability of quality generic drug products plays an increasingly important role...

Author(s): Alfredo García Arieta, PhD

DOI: 10.5639/gabij.2019.0801.005

15.075 views

Read more →

Pharma News

Published on 21 May 2019

Top developments in biosimilars during 2018

Submitted: 5 February 2019; Revised: 14 March 2019; Accepted: 20 March 2019; Published online first: 2 April 2019 The global market for biosimilars is valued at approximately US$4 billion, and...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2019.0801.004

8.655 views

Read more →